Medicare's Bet on Weight-Loss Drugs: $50 Copay, 18-Month Trial

Starting July 2026, Medicare covers three GLP-1 weight-loss drugs—Wegovy, Zepbound, and Foundayo—at a flat $50 monthly copay. That's a fraction of their $1,000-plus list prices. The program ends December 2027. CMS is treating it as a test run before deciding whether permanent coverage makes sense.